Apr, 2022

Global
News / General News
We published a Drug Research page.
Read More

Mar, 2022

Global
News / Press Releases
Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia
Astellas’ MOONLIGHT 1™ clinical trial evaluating investigational fezolinetant 30 mg administered once daily TOKYO, March 15, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced topline results from the ongoing Phase 3 MOONLIGHT 1™ clinical trial investigating the efficacy and safety of fezolinetant, an investigational oral, nonhormonal...
Read More
Global
News / Stories
We published a story: “Reinvigorating the immune system to find new ways to cure cancer.”
Read More
Global
News / Press Releases
Astellas Announces Completion of Acquisition of Own Shares, and Cancellation of Treasury Stock
- Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act- TOKYO, March 10, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the status and the...
Read More
Global
News / General News
UPDATE ON UKRAINE
Our thoughts are with the people of Ukraine, and we hope for a swift and peaceful resolution to the situation. Our priority is on the safety of Astellas Ukraine employees and their families. Also, we are ensuring on-going partnership and connectivity with suppliers, distributors and key stakeholders to do our best efforts for continuous supply for patients. We have taken steps to support the...
Read More

May, 2024

Global
News / Press Releases
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, “Poseida”) today announced that Xyphos Biosciences, Inc., (a wholly...
Read More

Apr, 2024

Global
News / Press Releases
Change in Definition of Core Basis in Financial Results
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at the meeting of the Board of Directors held today, it decided to change the definition of core basis in consolidated financial statements from the fiscal year 2024 (FY2024) ending March 31, 2025 onward. Astellas has been applying International Financial Reporting Standards...
Read More
Global
News / Press Releases
Change of Directors
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 19th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 20, 2024. 1...
Read More
Global
News / Press Releases
Astellas’ XTANDITM (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI can be given alone or in combination with androgen deprivation therapy Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide...
Read More
Global
News / Press Releases
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, “Takeda”), Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), and Sumitomo Mitsui Banking Corporation (President & CEO: Akihiro Fukutome, “SMBC”) today announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company. The...
Read More

Apr, 2024

Global
News / IR
Posted Financial Results for FY2023
Read More
Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Feb, 2024

Global
News / IR
Posted Financial Results for Q3/FY2023
Read More

Dec, 2023

Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Nov, 2023

Global
News / IR
Posted Financial Results for Q2/FY2023
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom